Carcell Biopharma ("Carcell") is a global biotech company launched by EVX Ventures. With an innovative “hub-and-spoke” business model, Carcell accelerates innovations in and translation of next-generation cell and gene therapies. Carcell has two lead technology platforms. The first technological platform creates engineered red blood cells (eRBC) for allogeneic cell therapy against autoimmune diseases and cancer. The second technological platform is a lipid nanoparticle (LNP) platform that has a proprietary library and high throughput screening capabilities for effective nucleic acid delivery.
Company Details
- Employees
- 8
- Founded
- -
- Address
- #166 Meiyue Road, Blk 122, Level 2, Shanghai Pilot Free-Trade Zone, Shanghai,201208,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.carcell.com
- HQ
- Shanghai
Carcell Biopharma Questions
Carcell Biopharma's website is https://www.carcell.com
Carcell Biopharma's LinkedIn profile is https://cn.linkedin.com/company/carcell-biopharma
Carcell Biopharma has
8 employees.
View email and phone details for 8
employees at Carcell Biopharma.
Carcell Biopharma's industry is
Biotechnology Research
Carcell Biopharma's top competitors are
Esco,
Singzyme,
Nuevocor,
Clavystbio,
Hummingbird Bioscience,
Axcynsis Therapeutics,
Evx Ventures,
Mirxes,
Lerna Biopharma,
Carmine Therapeutics.
Carcell Biopharma's categories are Biotechnology Research
Carcell Biopharma's founding year is 2021
